Anesthetic drug development: Novel drugs and new approaches

Surgical Neurology International

Volumn 4, Issue SUPPL1, 2013, Pages

  Chitilian, Hovig V ^a   Eckenhoff, Roderic G ^b   Raines, Douglas E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anesthetic; etomidate; midazolam; propofol

Indexed keywords

1 AMINOANTHRACENE; 4 AMINOBUTYRIC ACID A RECEPTOR; ANESTHETIC AGENT; AZD 3043; BENZODIAZEPINE DERIVATIVE; CARBOETOMIDATE; DRUG METABOLITE; ESMOLOL; ETOMIDATE; FLUMAZENIL; JM 1232; METHOXYCARBONYL ETOMIDATE; MIDAZOLAM; PF 0713; PROPOFOL; REMIFENTANIL; REMIMAZOLAM; THIOPENTAL; UNCLASSIFIED DRUG;

ANESTHESIA MECHANISM; ANESTHESIOLOGY; ANESTHETIC RECOVERY; ARTICLE; BINDING KINETICS; CARDIOVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CLINICAL PRACTICE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HYPNOSIS; KIDNEY FAILURE; MOLECULAR LIBRARY; NONHUMAN; OPTIMAL DRUG DOSE; PHENOTYPE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; STEROIDOGENESIS; TREATMENT OUTCOME;

EID: 84877956539     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.109179     Document Type: Article

References (66)

1. Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A Placebo-and midazolam-controlled, phase I, single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012;115:274-83.
2. Bali M, Akabas MH. Defining the propofol binding site location on the GABAA receptor. Mol Pharmacol 2004;65:68-76.
3. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, Perrotta DM, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995;333:147-54.
4. Bodor N, Buchwald P. Soft drug design: General principles and recent applications. Med Res Rev 2000;20:58-101.
5. Boulieu R, Lehmann B, Salord F, Fisher C, Morlet D. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients. Eur J Drug Metab Pharmacokinet 1998;23:255-8.
6. Butts C, Xi J, Brannigan G, Klein ML, Saad AA, Venkatachalan SP, et al. Identification of a fluorescent general anesthetic,1-aminoanthracene. Proc Natl Acad Sci U S A 2009;106:6501-6.
7. Campagna-Slater V, Weaver DF. Anaesthetic binding sites for etomidate and propofol on a GABAA receptor model. Neurosci Lett 2007;418:28-33.
8. Chiba S, Nishiyama T, Yamada Y. The antinociceptive effects and pharmacological properties of JM-1232(-): A novel isoindoline derivative. Anesth Analg 2009;108:1008-14.
9. Choi YF, Wong TW, Lau CC. Midazolam is more likely to cause hypotension than etomidate in emergency department rapid sequence intubation. Emerg Med J 2004;21:700-2.
10. Claeys MA, Gepts E, Camu F. Haemodynamic changes during anaesthesia induced and maintained with propofol. Br J Anaesth 1988;60:3-9.
11. Cotten JF, Forman SA, Laha JK, Cuny GD, Husain SS, Miller KW, et al. Carboetomidate: A pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010;112:637-44.
12. Cotten JF, Husain SS, Forman SA, Miller KW, Kelly EW, Nguyen HH, et al. Methoxycarbonyl-etomidate: A novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009;111:240-9.
13. Cotten JF, Le Ge R, Banacos N, Pejo E, Husain SS, Williams JH, et al. Closed-loop continuous infusions of etomidate and etomidate analogs in rats: A comparative study of dosing and the impact on adrenocortical function. Anesthesiology 2011;115:764-73.
14. de Jong FH, Mallios C, Jansen C, Scheck PA, Lamberts SW. Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984;59:1143-7.
15. den Brinker M, Hokken-Koelega AC, Hazelzet JA, de Jong FH, Hop WC, Joosten KF. One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis. Intensive Care Med 2008;34:163-8.
16. Doenicke A, Wagner E, Beetz KH. Arterial blood gas analyses following administration of three short-acting i.v. hypnotics (propanidid, etomidate, methohexitone). Anaesthesist 1973;22:353-6.
17. Dundee JW, Robinson FP, McCollum JS, Patterson CC. Sensitivity to propofol in the elderly. Anaesthesia 1986;41:482-5.
18. Egan TD, Obara S, Jenkins TE, Jaw-Tsai SS, Amagasu S, Cook DR, et al. AZD-3043, A novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology 2012;116:1267-77.
19. Emerson D, Liao Z, Eckenhoff RG, Dmochowski IJ. A novel fluorescent general anesthetic enables imaging of the in vivo sites of action. Anesthesiology 2012;116:1363.
20. Forman SA. Molecular approaches to improving general anesthetics. Anesthesiol Clin 2010;28:761-71.
21. Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology 2011;114:695-707.
22. Fragen RJ, Shanks CA, Molteni A, Avram MJ. Effects of etomidate on hormonal responses to surgical stress. Anesthesiology 1984;61:652-6.
23. Fudickar A, Bein B, Tonner PH. Propofol infusion syndrome in anaesthesia and intensive care medicine. Curr Opin Anaesthesiol 2006;19:404-10.
24. Ge R, Pejo E, Husain SS, Cotten JF, Raines DE. Encephalographic and hypnotic recoveries following brief and prolonged infusions of etomidate and optimized soft etomidate analogs. Anesthesiology 2012;117:1037-43.
25. Godefroi EF, Janssen PA, Vandereycken CA, Vanheertum AH, Niemegeers CJ. Dl-1-(1-Arylalkyl) Imidazole-5-Carboxylate Esters. A novel type of hypnotic agents. J Med Chem 1965;8:220-3.
26. Huggins DJ, Sherman W, Tidor B. Rational approaches to improving selectivity in drug design. J Med Chem 2012;55:1424-44.
27. Husain SS, Pejo E, Ge R, Raines DE. Modification of methoxycarbonyl etomidate′s interester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of hypnotic action. Anesthesiology 2012;117:1027-36.
28. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, et al. Quantitative high throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A 2006;103:11473-8.
29. Jackson WL Jr. Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?: A critical appraisal. Chest 2005;127:1031-8.
30. Kanamitsu N, Osaki T, Itsuji Y, Yoshimura M, Tsujimoto H, Soga M. Novel water-soluble sedative-hypnotic agents: Isoindolin-1-one derivatives. Chem Pharm Bull (Tokyo) 2007;55:1682-8.
31. Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. CNS 7056: A novel ultra-short-acting Benzodiazepine. Anesthesiology 2007;107:60-6.
32. Krasowski MD, Jenkins A, Flood P, Kung AY, Hopfinger AJ, Harrison NL. General anesthetic potencies of a series of propofol analogs correlate with potency for potentiation of gamma-aminobutyric acid (GABA) current at the GABA (A) receptor but not with lipid solubility. J Pharmacol Exp Ther 2001;297:338-51.
33. Laggner C, Kokel D, Setola V, Tolia A, Lin H, Irwin JJ, et al. Chemical informatics and target identification in a zebrafish phenotypic screen. Nat Chem Biol 2011;8:144-6.
34. Lea WA, Jadhav A, Xi J, Lu L, Austin CP, Simeonov A, et al. A high throughput approach for identification of novel general anesthetics. PLoS One 2009;4:e7150.
35. Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983;1:1270.
36. Liu R, Loll PJ, Eckenhoff RG. Structural basis for high affinity volatile anesthetic binding in a natural 4-helix bundle protein. FASEB J 2005;19:567-76.
37. Morgan M, Lumley J, Whitwam JG. Etomidate, a new water-soluble non-barbiturate intravenous induction agent. Lancet 1975;1:955-6.
38. Nishiyama T, Chiba S, Yamada Y. Antinociceptive property of intrathecal and intraperitoneal administration of a novel water-soluble isoindolin-1-one derivative, JM 1232 (-) in rats. Eur J Pharmacol 2008;596:56-61.
39. Nordt SP, Clark RF. Midazolam: A review of therapeutic uses and toxicity. J Emerg Med 1997;15:357-65.
40. Oakley S, Vedula S, Xi J, Bu W, Liu R, Eckenhoff RG, et al. Recognition of anesthetic barbituates by a protein binding site: A high resolution structural analysis. PLoS One 2012;7:e32070.
41. Otterspoor LC, Kalkman CJ, Cremer OL. Update on the propofol infusion syndrome in ICU management of patients with head injury. Curr Opin Anaesthesiol 2008;21:544-51.
42. Ouellet H, Podust LM, de Montellano PR. Mycobacterium tuberculosis CYP130: Crystal structure, biophysical characterization, and interactions with antifungal azole drugs. J Biol Chem 2008;283:5069-80.
43. Pejo E, Cotten JF, Kelly EW, Le Ge R, Cuny GD, Laha JK, et al. In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate. Anesth Analg 2012;115:297-304.
44. Pejo E, Feng Y, Chao W, Cotten JF, Le Ge R, Raines DE. Differential effects of etomidate and its pyrrole analogue carboetomidate on the adrenocortical and cytokine responses to endotoxemia. Crit Care Med 2012;40:187-92.
45. Pejo E, Ge R, Banacos N, Cotten JF, Husain SS, Raines DE. Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite after continuous infusions of a rapidly metabolized eomidate analog in rats. Anesthesiology 2012;116:1057-65.
46. Roumen L, Sanders MP, Pieterse K, Hilbers PA, Plate R, Custers E, et al. Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. J Comput Aided Mol Des 2007;21:455-71.
47. Ruesch D, Neumann E, Wulf H, Forman SA. An allosteric coagonist model for propofol effects on alpha1beta2 gamma 2L gamma-aminobutyric acid type A receptors. Anesthesiology 2012;116:47-55.
48. Rusch D, Forman SA. Classic benzodiazepines modulate the open-close equilibrium in alpha1beta2 gamma 2L gamma-aminobutyric acid type A receptors. Anesthesiology 2005;102:783-92.
49. Saari TI, Uusi-Oukari M, Ahonen J, Olkkola KT. Enhancement of GABAergic activity: Neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. Pharmacol Rev 2011;63:243-67.
50. Scott EE, White MA, He YA, Johnson EF, Stout CD, Halpert JR. Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9-A resolution: Insight into the range of P450 conformations and the coordination of redox partner binding. J Biol Chem 2004;279:27294-301.
51. Seward HE, Roujeinikova A, McLean KJ, Munro AW, Leys D. Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode. J Biol Chem 2006;281:39437-43.
52. Siegel LC, Konstantatos A. PF0713 produced rapid induction of general anesthesia without injection pain in a phase 1 study. Anesthesiology 2009;A463. Available from: http://www.asaabstracts.com/strands/asaabstracts/abstract. htm;jsessionid=DA93833E41FF06A7178351B6D992EC52?year=2008&index= 2&absnum=1096.
53. Siegel LC, Pelc LR, Shaff K. Dose response of PF0713, a novel investigational intravenous anesthetic agent. Anesthesiology 2008;A463. Available from: http://www.asaabstracts.com/strands/asaabstracts/abstract. htm;jsessionid=DA93833E41FF06A7178351B6D992EC52?year=2008&index= 2&absnum=1096.
54. Sigel E. Mapping of the benzodiazepine recognition site on GABA (A) receptors. Curr Top Med Chem 2002;2:833-9.
55. Skues MA, Prys-Roberts C. The pharmacology of propofol. J Clin Anesth 1989;1:387-400.
56. Sneyd JR, Rigby-Jones AE. New drugs and technologies, intravenous anaesthesia is on the move (again). Br J Anaesth 2010;105:246-54.
57. Sneyd JR, Rigby-Jones AE, Cross M, Tominaga H, Shimizu S, Ohkura T, et al. First human administration of MR04A3: A novel water-soluble nonbenzodiazepine sedative. Anesthesiology 2012;116:385-95.
58. Takamatsu I, Sekiguchi M, Yonamine R, Wada K, Kazama T. The effect of a new water-soluble sedative-hypnotic drug, JM-1232(-), on long-term potentiation in the CA1 region of the mouse hippocampus. Anesth Analg 2011;113:1043-9.
59. Uemura S, Fujita T, Sakaguchi Y, Kumamoto E. Actions of a novel water-soluble benzodiazepine-receptor agonist JM-1232(-) on synaptic transmission in adult rat spinal substantia gelatinosa neurons. Biochem Biophys Res Commun 2012;418:695-700.
60. Upton R, Martinez A, Grant C. A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems. Br J Pharmacol 2008 155:52-61.
61. Upton RN, Martinez AM, Grant C. Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheep. Br J Anaesth 2009;103:848-57.
62. Vedula S, Brannigan G, Economou NJ, Xi J, Hall MA, Dailey WP, et al. A unitary anesthetic protein binding site at high resolution. J Biol Chem 2009;284:24176-84.
63. Vinclair M, Broux C, Faure P, Brun J, Genty C, Jacquot C, et al. Duration of adrenal inhibition following a single dose of etomidate in critically ill patients. Intensive Care Med 2008;34:714-9.
64. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984;310:1415-21.
65. Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984;39:973-81.
66. Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A Placebo and Midazolam-Controlled Phase I Single Ascending Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056). Part II: Population Pharmacokinetic and Pharmacodynamic Modeling and Simulation. Anesth Analg 2012;115:284-96.